Heinemann Lutz, Drossel Diana, Freckmann Guido, Kulzer Bernhard
Science & Co, Düsseldorf, Germany.
Eschweiler, Germany.
J Diabetes Sci Technol. 2016 Nov 1;10(6):1382-1387. doi: 10.1177/1932296816666536. Print 2016 Nov.
The estimation is that every third to fourth patient with diabetes suffers from some degree of diabetic retinopathy. Medical products for insulin administration (such as insulin pens and pumps) or glucose monitoring not optimized to the needs of these patients' represent a high barrier for optimal diabetes therapy in daily practice. To date, the number of devices suitable for visually impaired and blind patients with diabetes is scarce. This manuscript outlines the specific needs of this patient group with regard to systems for insulin administration, blood glucose measurement, and continuous glucose monitoring. We see the clear need for a policy requirement for manufacturers to provide accessible/user friendly technical aids for visually impaired and blind patients with diabetes. This would represent an important step toward improving the situation for this impressively large patient group.
据估计,每三到四位糖尿病患者中就有一位患有某种程度的糖尿病视网膜病变。用于胰岛素给药的医疗产品(如胰岛素笔和胰岛素泵)或未根据这些患者需求进行优化的血糖监测,在日常实践中对优化糖尿病治疗构成了很大障碍。迄今为止,适合视力受损和失明糖尿病患者的设备数量稀少。本手稿概述了该患者群体在胰岛素给药系统、血糖测量和持续血糖监测方面的特殊需求。我们清楚地看到,需要制定一项政策要求,让制造商为视力受损和失明的糖尿病患者提供无障碍/用户友好型技术辅助工具。这将是朝着改善这个庞大患者群体的状况迈出的重要一步。